Aryl hydrocarbon receptor upregulates IL-1β expression in hCMEC/D3 human cerebral microvascular endothelial cells after TCDD exposure. (June 2017)

• Record Type: Journal Article
• Authors: Jacob, Aude; Tomkiewicz-Raulet, Céline; Jamet, Charlotte; Bendayan, Reina; Massicot, France; Coumoul, Xavier; Declèves, Xavier
• Is Part Of: Toxicology in vitro. Volume 41(2017)
• Page Start: 200
• Page End: 204
• Publication Date: 2017-06
• Subjects: Aryl hydrocarbon receptor -- Blood-brain barrier -- hCMEC/D3 -- Pro-inflammatory cytokines; Toxicity testing -- In vitro -- Periodicals; Toxicology -- Periodicals; 615.9
• DOI: 10.1016/j.tiv.2017.03.001
• Languages: English
• ISSNs: 0887-2333

Abstract

Abstract: The AhR is a cytosolic ligand-dependent transcription factor activated by both endogenous and exogenous chemicals. It can regulate expression of many target genes including some inflammatory cytokines and chemokines. To date AhR implication in the regulation of inflammatory cytokines and chemokines at human cerebral endothelium has not been addressed. In the present study, we investigated whether AhR could regulate the expression of two pro-inflammatory cytokines and one chemokine i.e. IL-1β, IL-6 and IL-8 in the hCMEC/D3 human cerebral microvascular endothelial cell line. Exposure to TCDD increased IL-1β mRNA expression levels in hCMEC/D3. By using small interfering RNA against AhR we demonstrated that TCDD effects on IL-1β expression were mediated through AhR activation. Regarding IL-6 and IL-8, TCDD exposure had little or no effect on their mRNA levels in hCMEC/D3. In conclusion, our findings suggest that AhR-mediated IL-1β regulation in cerebral endothelium could induce BBB breakdown and contribute to the pathogenesis of a variety of neurologic disorders. Highlights: Activation of AhR by TCDD notably increases mRNA levels of IL1- β in hCMEC/D3 cells. Regarding IL-6 and IL-8, exposure to TCDD had little or no effect on their mRNA expression levels respectively. Knocking-down AhR in hCMEC/D3 cells abolished effect of TCDD on IL1-beta mRNA levels.